# Versartis Long-Term Safety Study of Somavaratan

> **NCT02068521** · PHASE2,PHASE3 · TERMINATED · sponsor: **Versartis Inc.** · enrollment: 385 (actual)

## Conditions studied

- Pediatric Growth Hormone Deficiency

## Interventions

- **DRUG:** somavaratan

## Key facts

- **NCT ID:** NCT02068521
- **Lead sponsor:** Versartis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-03
- **Primary completion:** 2017-11-17
- **Final completion:** 2017-11-17
- **Target enrollment:** 385 (ACTUAL)
- **Why stopped:** The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02068521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02068521, "Versartis Long-Term Safety Study of Somavaratan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02068521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*